pasireotide; pasireotide diaspartate (Signifor)
Jump to navigation
Jump to search
Indications
- treatment of Cushing's disease
- treatment of acromegaly[3]
Dosage
- subcutaneous injection twice daily
Adverse effects
Mechanism of action
More general terms
References
- ↑ FDA News Release: Dec. 14, 2012 FDA approves Signifor, a new orphan drug for Cushing's disease http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332351.htm
- ↑ Novartis: Media releases Novartis drug Signifor<TM> gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder. http://www.novartis.com/newsroom/media-releases/en/2012/1665290.shtml
- ↑ 3.0 3.1 Colao A, Bronstein MD, Freda P et al Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014 Mar;99(3):791-9. PMID: https://www.ncbi.nlm.nih.gov/pubmed/24423324 Free PMC Article